Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2146753 | 0.95 | CTSS (0.90) | CTSSCTSK | |
| SCHEMBL2146516 | 0.93 | CTSS (0.86) | CTSSCTSK | |
| SCHEMBL13642030 | 0.90 | CTSS (0.82) | CTSSCTSK | |
| SCHEMBL1629550 | 0.89 | CTSS (1.00) | CTSSCTSK | |
| SCHEMBL2146863 | 0.88 | CTSS (0.78) | CTSSCTSK | |
| Hydrochloric Acid SCHEMBL1629816 | 0.88 | CTSS (0.98) | CTSSCTSK | |
| Trifluoroacetic Acid SCHEMBL2146528 | 0.88 | CTSS (0.78) | CTSSCTSK | |
| SCHEMBL6898033 | 0.88 | CTSS (0.78) | CTSSCTSK | |
| SCHEMBL13584629 | 0.88 | CTSS (0.79) | CTSSCTSK | |
| SCHEMBL2146720 | 0.87 | CTSS (0.77) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115126-B2 | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-08-25 | — | — | US | claimed |
| EP-2523954-B1 | 1H-[1,2,3]TRIAZOLO[4,5-C]PYRIDINE-4- CARBONITRILE DERIVATIVES AS CATHEPSIN S INHIBITORS | MERCK SHARP & DOHME (NL) | 2014-04-16 | — | — | EP | claimed |
| EP-2523954-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD Oss B.V. (NL) | 2012-11-21 | — | — | EP | claimed |
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD OSS B.V. (NL) | 2012-11-08 | — | — | US | claimed |
| WO-2011086125-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2011-07-21 | — | — | WO | claimed |
| US-9115126-B2 | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-08-25 | — | — | US | disclosed |
| US-9115126-B2 | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-08-25 | — | — | US | disclosed |
| US-9115126-B2 | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-08-25 | — | — | US | disclosed |
| EP-2523954-B1 | 1H-[1,2,3]TRIAZOLO[4,5-C]PYRIDINE-4- CARBONITRILE DERIVATIVES AS CATHEPSIN S INHIBITORS | MERCK SHARP & DOHME (NL) | 2014-04-16 | — | — | EP | disclosed |
| EP-2523954-B1 | 1H-[1,2,3]TRIAZOLO[4,5-C]PYRIDINE-4- CARBONITRILE DERIVATIVES AS CATHEPSIN S INHIBITORS | MERCK SHARP & DOHME (NL) | 2014-04-16 | — | — | EP | disclosed |
| EP-2523954-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD Oss B.V. (NL) | 2012-11-21 | — | — | EP | disclosed |
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD OSS B.V. (NL) | 2012-11-08 | — | — | US | disclosed |
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD OSS B.V. (NL) | 2012-11-08 | — | — | US | disclosed |
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | MSD OSS B.V. (NL) | 2012-11-08 | — | — | US | disclosed |
| WO-2011086125-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086125-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283239-A1 | 1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES | CTSS, CTSV, CTSZ | CTSS 1/4885CTSK 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.